Investments, Funding & Disinvestment

The acquisition comes as Bayer seeks to reinforce its position in ophthalmology amid growing biosimilar competition facing Eylea, which it co-developed with Regeneron.

The investment comes as Oman accelerates the modernization of its healthcare infrastructure through public-private collaboration and increased adoption of advanced medical technologies.

The project is backed by a conditional grant of up to C$5 million (US$3.6 million) from the Ontario government through the Invest Ontario Fund.

Photon Flash radiotherapy delivers radiation more than 100 times faster than conventional radiotherapy techniques, to reduce damage to surrounding healthy tissue while effectively targeting tumors.

If fully developed and commercialized, Huahui Health could receive up to US$1.9 billion in milestone-based payments, in addition to tiered royalties on future global sales.

The acquisition is expected to close by the end of the second quarter or early third quarter of 2026, pending regulatory approvals and customary closing conditions.

Through this expansion, the company aims to strengthen advanced manufacturing capabilities, support workforce development, and generate hundreds of construction-related jobs.

Thermo Fisher’s microbiology unit generated US$645 million in revenue in 2025 and operates within the company’s specialty diagnostics segment.

Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.

The acquisition brings Amicus Therapeutics fully under BioMarin’s global operations, integrating its late-stage and commercial-stage rare disease assets into BioMarin’s established infrastructure.